9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Estimated reading time: < 1 min

Condition

Tumors With CDK4/6 Pathway Activation

Estimated Enrollment: 106

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CLEE011XUS03

Study First Received: July 9, 2014

Last Updated: November 27, 2016

Estimated Primary Completion Date: April 2018

Primary Outcome Measures:

Clinical benefit rate associated with LEE011 treatment|Overall Response (OR) of Partial Response (PR) or greater|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Safety and tolerability

Sponsors and Collaborators:

Novartis Pharmaceuticals|Novartis

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02187783

Was this article helpful?
Views: 12